findmyKOL

Charles Wykoff, MD

Enriched profile

Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Houston Methodist Academic Institute · Retina Consultants of Texas

ORCIDNPI
Region🇺🇸 Bellaire, TX · South Central · United StatesSpecialtyOphthalmologyFocusRetinal Diseases and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Charles Wykoff is Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Houston Methodist Academic Institute at Retina Consultants of Texas. OpenAlex indexes 507 publications with 23,504 citations (h-index 67); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Charles Wykoff, MD, PHD, is Director of Research, Retina Consultants of Texas. The public record shows 507 publications with 23,504 citations (h-index 67), centered on Retinal Diseases and Treatments, Retinal Imaging and Analysis, Retinal and Optic Conditions. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 45 companies.

  • Most recent indexed publication: 2026 · Eye (London, England)
  • Top research focus: Retinal Diseases and Treatments
  • 12 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 45 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Macular Degeneration (AMD)4 trialsDiabetic Complications4 trialsDiabetic Retinopathy / DME4 trialsEdema3 trialsMacular Edema3 trialsRetinal Vein Occlusion2 trialsDiabetic Retinopathy2 trialsDilatation, Pathologic1 trialTelangiectasis1 trialGeographic Atrophy1 trialAtrophy1 trialIschemia1 trialRetinal Diseases1 trialPathologic Processes1 trial

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal and Optic ConditionsOcular Diseases and Behçet’s SyndromeOphthalmology and Visual Impairment Studies

Drugs & molecules

across trials, industry payments and publications
Eyleageneric · AfliberceptClinical trialsIndustry payments56Publications3Syfovregeneric · PegcetacoplanClinical trialsIndustry payments51Publications4Beovugeneric · BrolucizumabClinical trialsIndustry payments14Publications1

Works with

trial sponsors and companies reporting payments
Apellis Pharmaceuticals, Inc.Clinical trialsIndustry payments91Regeneron Pharmaceuticals, Inc.Clinical trialsIndustry payments57Abbvie Inc.Clinical trialsIndustry payments51

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
507publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

23,504citations

Total citations across indexed works.

67h-index

Hirsch index (OpenAlex). i10-index 240.

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials
45companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

45 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    56.1%
    Complement Inhibitor44%
    Pegcetacoplan100%
    Part B, office-administered126 patients
    Vascular Endothelial Growth Factor Inhibitor12.2%
    Aflibercept100%
    Part B, office-administered333 patients
  • Sensory organs

    43.4%
    Antineovascularisation agents36.3%
    Faricimab-svoa100%
    Part B, office-administered35 patients
    Vascular Endothelial Growth Factor Inhibitor6.2%
    Ranibizumab100%
    Part B, office-administered69 patients
  • Musculoskeletal

    0.3%
    Cyclooxygenase Inhibitor0.3%
    Ketorolac Tromethamine100%
    Part D47 patients
3 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

1 congress contribution (2018) across AMCP per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/charles-wykoff-7912702

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    retinaconsultantstexas.com

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultantstexas.com
  • Other

    asrs.org/find-a-specialist/profile/5346/Charles-C-Wykoff

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Vitreoretinal Diseases & Surgery Fellowship

    Bascom Palmer Eye Institute

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.houstonmethodist.org
  • Ophthalmology Residency

    Bascom Palmer Eye Institute

    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.houstonmethodist.org
  • MD

    Harvard Medical School

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.houstonmethodist.org
  • PhD

    University of Oxford (Marshall Scholarship)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultantstexas.com
  • Undergraduate degree

    Massachusetts Institute of Technology (Phi Beta Kappa)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultantstexas.com
  • Board certified

    American Board of Ophthalmology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultantstexas.com

Editorial & leadership roles

journal and society appointments
7 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.